Armistice Capital and Steven Boyd disclose 9.99% stake in Biodexa (BDRX)

Rhea-AI Filing Summary

Biodexa Pharmaceuticals Plc reports a Schedule 13G showing Armistice Capital, LLC and Steven Boyd beneficially own 283,502 ADS, representing 9.99% of the class as of 12/31/2025. The filing states the shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital is investment manager and Steven Boyd is managing member. The Reporting Persons report shared voting and dispositive power of 283,502 ADS and no sole voting or dispositive power. The Master Fund is identified as the direct holder and noted as having the right to receive dividends or sale proceeds.

Insights

Equity Ownership Analyst

Armistice Capital and its managing member report a near-10% stake in Biodexa via a managed fund.

The Schedule 13G discloses 283,502 ADS equal to 9.99% of the class as of 12/31/2025. The filing attributes the position to Armistice Capital Master Fund Ltd. with voting and dispositive authority exercised by Armistice Capital under an Investment Management Agreement.

Ownership is reported as shared voting and dispositive power of 283,502 ADS. The Master Fund is named as the direct holder and retains the right to dividends or sale proceeds. Subsequent filings would show changes to this stake.

Corporate Governance Specialist

Filing clarifies attribution and managerial control without asserting direct beneficial ownership by the Master Fund.

The statement explains Armistice Capital exercises voting and investment power under an Investment Management Agreement and that Steven Boyd, as managing member, may be deemed to beneficially own the securities. The Master Fund "disclaims beneficial ownership" due to its inability to vote or dispose of the securities.

Voting/dispositive powers are listed as shared only. Any effects from this position depend on future transactions or amendments filed with respect to holdings or voting intent.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Biodexa Pharmaceuticals Plc

(Name of Issuer)

American Depositary Shares, each representing four hundred ordinary shares

(Title of Class of Securities)

59564R880

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 59564R880

1

Names of Reporting Persons

Armistice Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 283,502.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 283,502.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

283,502.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 59564R880

1

Names of Reporting Persons

Steven Boyd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 283,502.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 283,502.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

283,502.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Biodexa Pharmaceuticals Plc
(b)	Address of issuer's principal executive offices: 1 Caspian Point Caspian Way, Cardiff, United Kingdom CF10 4DQ
Item 2.
(a)	Name of person filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b)	Address or principal business office or, if none, residence: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c)	Citizenship: Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)	Title of class of securities: American Depositary Shares, each representing four hundred ordinary shares
(e)	CUSIP No.: 59564R880
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 283,502
(b)	Percent of class: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 283,502
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 283,502 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Armistice Capital, LLC

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd - Managing Member
Date:	02/17/2026

Steven Boyd

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd
Date:	02/17/2026

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital report in Biodexa (BDRX)?

Armistice Capital reports beneficial ownership of 283,502 ADS, representing 9.99% of the class as of 12/31/2025. The filing attributes the position to Armistice Capital Master Fund Ltd., for which Armistice acts as investment manager.

Who is listed as the direct holder of the shares reported in the Schedule 13G?

The filing identifies Armistice Capital Master Fund Ltd. as the direct holder of the reported ADS. Armistice Capital is the fund's investment manager and exercises voting and investment power under an Investment Management Agreement.

What voting and dispositive powers are reported by the Reporting Persons?

The Reporting Persons disclose 0 sole voting and 0 sole dispositive power, and shared voting and dispositive power of 283,502 ADS, indicating shared authority over voting and disposition of the shares.

Does the Master Fund claim beneficial ownership of the reported ADS?

The Master Fund specifically disclaims beneficial ownership

Who signed the Schedule 13G for Armistice Capital and Steven Boyd?

The filing is signed by Steven Boyd in his capacity as Managing Member of Armistice Capital, dated 02/17/2026, and includes a joint filing statement covering both Reporting Persons.